scholarly journals Oxidative and Antioxidative Stress Status in Children with Inflammatory Bowel Disease as a Result of a Chronic Inflammatory Process

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Urszula Grzybowska-Chlebowczyk ◽  
Paulina Wysocka-Wojakiewicz ◽  
Martyna Jasielska ◽  
Bożena Cukrowska ◽  
Sabina Więcek ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Functional Gastrointestinal Disorders ◽  
Average Concentration ◽  
Average Density ◽  
Total Antioxidant ◽  
Oxidized Lipoprotein ◽  
Inflammatory Bowel ◽  
Antioxidative Stress ◽  
Atherosclerotic Process

Oxidative stress (OS) has been recently implicated in the disease pathogenesis in inflammatory bowel disease (IBD). The aim of the study was to evaluate oxidative and antioxidative stress status and the risk of the atherosclerotic process in children with IBD and functional gastrointestinal disorders (FGID). The prospective study included a group of 71 children during a period of 2 years. In all children, laboratory tests were performed and intima-media complex in the carotid artery was measured (IMC). Low values of OS were more frequent in children with IBD than in the FGID group. The average concentration of oxidized lipoprotein with average density (oxLDL) was lower in patients with IBD. Among patients with IBD, higher concentrations of oxLDL were recorded in patients with longer-duration disease and with higher concentrations of total cholesterol. In the IBD group, more often, higher concentrations of anti-oxLDL were recorded among patients with longer-duration disease. The obtained results did not support the hypothesis of total antioxidant capacity depletion and greater overall OS in patients with IBD. Patients with IBD with a longer duration of the disease have higher concentrations of oxLDL and anti-oxLDL.

scholarly journals Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor

2020 ◽  
Vol 9 (6) ◽  
pp. 1757 ◽  
Author(s):  
Stefano Bibbò ◽  
Carlo Romano Settanni ◽  
Serena Porcari ◽  
Enrico Bocchino ◽  
Gianluca Ianiro ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Metabolic Disorders ◽  
Fecal Microbiota Transplantation ◽  
Functional Gastrointestinal Disorders ◽  
Fecal Microbiota ◽  
Effective Treatment Option ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Inflammatory Bowel

In the past decade, fecal microbiota transplantation (FMT) has rapidly spread worldwide in clinical practice as a highly effective treatment option against recurrent Clostridioides difficile infection. Moreover, new evidence also supports a role for FMT in other conditions, such as inflammatory bowel disease, functional gastrointestinal disorders, or metabolic disorders. Recently, some studies have identified specific microbial characteristics associated with clinical improvement after FMT, in different disorders, paving the way for a microbiota-based precision medicine approach. Moreover, donor screening has become increasingly more complex over years, along with standardization of FMT and the increasing number of stool banks. In this narrative review, we discuss most recent evidence on the screening and selection of the stool donor, with reference to recent studies that have identified specific microbiological features for clinical conditions such as Clostridioides difficile infection, irritable bowel syndrome, inflammatory bowel disease, and metabolic disorders.

Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders

2017 ◽  
Vol 40 (3) ◽  
pp. 125-131 ◽  
Author(s):  
Maria Elena Lozoya Angulo ◽  
Ignacio de las Heras Gómez ◽  
Miriam Martinez Villanueva ◽  
Jose Antonio Noguera Velasco ◽  
Francisco Avilés Plaza
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Functional Gastrointestinal Disorders ◽  
Gastrointestinal Disorders ◽  
Faecal Calprotectin ◽  
Inflammatory Bowel

scholarly journals Low FODMAP Diet for Functional Gastrointestinal Symptoms in Quiescent Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3648
Author(s):  
Maria G. Grammatikopoulou ◽  
Dimitrios G. Goulis ◽  
Konstantinos Gkiouras ◽  
Meletios P. Nigdelis ◽  
Stefanos T. Papageorgiou ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Randomized Controlled Trials ◽  
Bowel Disease ◽  
Functional Gastrointestinal Disorders ◽  
Assessment Tools ◽  
Cell Phenotype ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Inflammatory Bowel ◽  
Fodmap Diet

A low FODMAP diet (LFD) has been hypothesized to relieve symptoms of functional gastrointestinal disorders (FGD) in patients with inflammatory bowel disease (IBD). The aim of the study was to systematically review the literature for randomized controlled trials (RCTs) assessing the effectiveness of the LFD in patients with IBD and FGD. Four databases were searched, but a meta-analysis was not performed due to methodological and outcomes heterogeneity. Four RCTs fulfilled the criteria, with three having some concerns in their risk of bias assessment. All interventions compared the LFDs against a “typical” or sham diet, spanning in duration from 21 days to 6 weeks. Quality of life was improved in two RCTs, while revealing inconsistent findings in the third trial, based on different assessment tools. The fecal assays revealed non-significant findings for most variables (fecal weight, pH, water content, gene count, and gut transit time) and inconsistent findings concerning stool frequency and short-chain fatty acids concentration. Levels of fecal calprotectin, CRP, or T-cell phenotype did not differ between intervention and comparator arms. Two RCTs reported a reduction in abdominal pain, while results concerning pain duration and bloating were inconsistent. In one trial, energy intake was considerably reduced among LFD participants. Regarding gut microbiota, no differences were noted. A considerable degree of methodological and outcome heterogeneity was observed, paired with results inconsistency. The available data are not sufficient to justify the claim that an LFD induces relief of FGD symptoms, although it may pave the way to a placebo response.

Sign in / Sign up

Export Citation Format

Share Document